Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. Galafold ...

Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, ...

With significant upside potential and hedge fund interest, Amicus Therapeutics, Inc. (NASDAQ:FOLD) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Goldman ...

Amicus Therapeutics (FOLD) reported Q3 results that caught investors’ attention, posting GAAP profitability along with solid revenue gains from its rare disease therapies. Global expansion and ...

Courtly Observations is a recurring series by Erwin Chemerinsky that focuses on what the Supreme Court’s decisions will mean for the law, for lawyers and lower courts, and for people’s lives. Please ...

The Supreme Court is, apparently, reading its amicus briefs — and one of them may provide an offramp from immediately having to decide whether President Trump has the power to deploy the National ...

Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...

A recent upgrade from a Needham analyst, who has shifted Amicus Therapeutics (FOLD) to a buy rating, is drawing attention. The analyst points to an improved outlook for the company, which could ...

Today, nonprofit, nonpartisan civil rights and racial justice organizations filed an amicus brief in support of the plaintiffs’ motions for preliminary injunction in League of United Latin American ...

Senior advocate Indira Jaising argued in Supreme Court against the government's stance on the age of consent, asserting that criminalizing consensual sexual activity between 16-18 year olds violates ...

According to Cofounder and partner at Amicus Capital, Mahesh Parasuraman, the fund had exceeded its target corpus of $200 Mn The India-focussed fund was launched in March 2023 which aims to back 10-12 ...